|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
R, Torre L and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwise for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hemminki K, Li X and Vaittinen P: Time
trends in the incidence of cervical and other genital squamous cell
carcinomas and adenocarcinomas in Sweden, 1958–1996. Eur J Obstet
Gynecol Reprod Biol. 101:64–69. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gunnell AS, Ylitalo N, Sandin S, Sparén P,
Adami HO and Ripatti S: A longitudinal Swedish study on screening
for squamous cell carcinoma and adenocarcinoma: Evidence of
effectiveness and overtreatment. Cancer Epidemiol Biomarkers Prev.
16:2641–2648. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Screening SNC, Registry. Förebyggande av
livmoderhalscancer i Sverige 2017, . Available from. http://www.nkcx.se/templates/_rsrapport_2017.pdf
|
|
5
|
Andrae B, Kemetli L, Sparén L, Strander B,
Ryder W, Dillner J and Törnberg S: Screening-preventable cervical
cancer risks: Evidence from a nationwide audit in Sweden. J Natl
Cancer Inst. 100:622–629. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ebisch R, Rutten D, IntHout J, Melchers W,
Massuger L, Bulten J, Bekkers R and Siebers A: Long-lasting
increased risk of human papillomavirus-related carcinomas and
premalignancies after cervical intraepithelial neoplasia grade 3: A
population-based cohort study. J Clin Oncol. 35:2542–2550. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pettersson BF, Hellman K, Vaziri R,
Andersson S and Hellström AC: Cervical cancer in the screening era:
Who Fell victim in spite of successful screening programs? J
Gynecol Oncol. 22:76–82. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Strander B, Andersson-Ellström A, Milsom I
and Sparén P: Long term risk of invasive cancer after treatment for
cervical intraepithelial neoplasia grade 3: Population based cohort
study. BMJ. 335:10772007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hoffman S, Le T, Lockhart A, Sanusi A, Dal
Santo L, Davis M, McKinney D, Brown M, Poole C, Willame C and Smith
JS: Patterns of persistent HPV infection after treatment for
cervical intraepithelial neoplasia (CIN): A systematic review. Int
J Cancer. 141:8–23. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Arbyn M, Ronco G, Anttila A, Meijer CJ,
Poljak M, Ogilvie G, Koliopoulos G, Nauclen P, Sankaranarayanan R
and Peto J: Evidence regarding human papillomavirus testing in
secondary prevention of cervical cancer. Vaccine. 30 (Suppl
5):F88–F99. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brismar S, Johansson B, Borjesson M, Arbyn
M and Andersson S: Follow-up after treatment of cervical
intraepithelial neoplasia by human papillomavirus genotyping. Am J
Obstet Gynecol. 201:17.e1–e8. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kocken M, Uijterwaal M, de Vries A,
Berkhof J, Ket J, Helmerhorst J and Meijer C: High-risk
papillomavirus testing versus cytology in predicting post-treatment
disease in women treated for high-grade cervical disease: A
systematic review and meta-analysis. Gynecol Oncol. 125:500–507.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Persson M, Brismar Wendel S, Ljungblad L,
Johansson B, Weiderpass E and Andersson S: High-risk human
papillomavirus E6/E7 mRNA and L1 DNA as markers of
residual/recurrent cervical intraepithelial neoplasia. Oncol Rep.
28:346–352. 2012.PubMed/NCBI
|
|
14
|
Garutti P, Borghi C, Bedoni C, Bonaccorsi
G, Greco P, Tognon M and Martini F: HPV-based strategy in follow-up
of patients treated for high-grade cervical intra-epithelial
neoplasia: 5-year results in a public health surveillance setting.
Eur J Obstet Gynecol Reprod Biol. 210:236–241. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bruhn L, Andersen S and Hariri J:
HPV-testing versus HPV-cytology co-testing to predict the outcome
after conization. Acta Obstet Gynecol Scand. 97:758–765. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hermansson RS, Olovsson M, Hoxell E and
Lindström AK: HPV prevalence and HPV-related dysplasia in elderly
women. PLoS One. 13:e01893002018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rodriguez A, Schiffman M, Herrero R,
Hildesheim A, Bratti C, Sherman M, Solomon D, Guillén D, Alfaro M,
Morales J, et al: Longitudinal study of human papillomavirus
persistence and cervical intraepithelial neoplasia grade 2/3:
Critical role of duration of infection. J Natl Cancer Inst.
102:315–324. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Plummer M, Schiffman M, Castle P,
Maucort-Boulch D and Wheeler C: A 2-year prospective study of human
papillomavirus persistence among women with a cytological diagnosis
of atypical squamous cells of undetermined significance or
low-grade squamous intraepithelial lesion. J Infect Dis.
195:1582–1589. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Alder S, Megyessi D, Sundström K,
Östensson E, Mints M, Belkić K, Arbyn M and Andersson S: Incomplete
excision of cervical intraepithelial neoplasia as a predictor of
the risk of recurrent disease-a 16 year follow-up study. Am J
Obstet Gynecol. 222:172e1–172e12. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Arbyn M, Redman C, Verdoodt F, Kyrgiou M,
Tzafetas M, Ghaem-Maghami S, Petry KU, Leeson S, Bergeron C,
Nieminen P, et al: Incomplete excision of cervical precancer as a
predictor of treatment failure: A systematic review and
meta-analysis. Lancet Oncol. 18:1665–1679. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fernández-Montolí ME, Tous S, Medina G,
Castellarnau M, García-Tejedor A and de Sanjosé S: Long-term
predictors of residual or recurrent cervical intraepithelial
neoplasia 2–3 after treatment with a large loop excision of the
transformation zone: A retrospective study. BJOG. 127:377–387.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Reich O, Pickel H, Lahousen M, Tamussino K
and Winter R: Cervical intraepithelial neoplasia III: long-term
outcome after cold-knife conization with clear margins. Obstet
Gynecol. 97:428–430. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Reich O, Lahousen M, Pickel H, Tamussino K
and Winter R: Cervical intraepithelial neoplasia III: Long-term
follow-up after cold-knife conization with involved margins. Obstet
Gynecol. 99:193–196. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ghaem-Maghami S, Sagi S, Majeed G and
Soutter WP: Incomplete excision of cervical intraepithelial
neoplasia and risk of treatment failure: A meta-analysis. Lancet
Oncol. 8:985–993. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Östensson E, Belkić K, Ramqvist T, Mints M
and Andersson S: Self-sampling for high-risk human papillomavirus
as a follow-up alternative after treatment of high-grade cervical
intraepithelial neoplasia. Oncol Lett. 21:2402021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Alder S: Prevention of Cervical Cancer in
Countries with High and Low Incidence of the Disease. Doctoral
Dissertation Stockholm Sweden: Karolinska Institute; 2018
|
|
27
|
Andersson S, Belkić K, Mints M and
Östensson E: Is self-sampling to test for HPV an acceptable option
among women who have been treated for high-grade cervical
intraepithelial neoplasia? PLoS One. 13:e01990382018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Andersson S, Belkić K, Safer Demirbüker S,
Mints M and Östensson E: Perceived cervical cancer risk among women
treated for high-grade cervical intraepithelial neoplasia: The
importance of specific knowledge. PLoS One. 12:e1901562017.
View Article : Google Scholar
|
|
29
|
Richart RM: Cervical intraepithelial
neoplasia. Pathol Annu. 8:301–328. 1973.PubMed/NCBI
|
|
30
|
Jordan J, Martin-Hirsch P, Arbyn M,
Schenck U, Baldauf JJ, Da Silva D, Anttila A, Nieminen P and
Prendiville W: European guidelines for clinical management of
abnormal cervical cytology-part-2. Cytopathology. 20:5–16. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Solomon D, Davey D, Kurman R, Moriarty A,
O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T, et al:
The 2001 Bethesda System: Terminology for reporting results of
cervical cytology. JAMA. 287:2114–2119. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Martin-Hirsch PL, Paraskevaidis E, Bryant
A, Dickinson HO and Keep SL: Surgery for cervical intraepithelial
neoplasia. Cochrane Database Syst Rev. CD0013182010.doi:
10.1002/14651858.CD001318.pub2. PubMed/NCBI
|
|
33
|
Ghaem-Maghami S, De-Silva D, Tipples M,
Lam S, Perryman K and Soutter W: Determinants of success in
treating cervical intraepithelial neoplasia. BJOG. 118:679–684.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fallani MG, Penna C, Fambrini M and
Marchionni M: Laser CO2 vaporization for high-grade
cervical intraepithelial neoplasia: A long-term follow-up series.
Gynecol Oncol. 91:130–133. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wongtiraporn W and Laiwejpithaya S,
Sangkarat S, Benjapibal M, Rattanachaiyanont M, Ruengkhachorn I,
Chaopotong P and Laiwejpithaya S: Long term outcomes of laser
conization for high grade cervical intraepithelial neoplasia in
Thai women. Asian Pac J Cancer Prev. 15:7757–7761. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Frank J: The colposcopic examination. J
Midwifery Womens Health. 53:447–452. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Manley K, Simms R, Platt S, Patel A and
Bahl R: Unsatisfactory colposcopy: Clinical decision making in
conditions of uncertainty. BMC Med Inform Decis Mak. 17:1252017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Baasland I, Hagen B, Vogt C, Valla M and
Romundstad PR: Colposcopy and additive diagnostic value of biopsies
from colposcopy-negative areas to detect cervical dysplasia. Acta
Obstet Gynecol Scand. 95:1258–1263. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bogani G, Pinelli C, Chiappa V, Martinelli
F, Lopez S, Ditto A and Rapagliesi F: Age-specific predictors of
cervical dysplasia recurrence after primary conization: Analysis of
3,212 women. J Gynecol Oncol. 31:e602020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Andersson S, Larson B, Hjerpe A,
Silfverswärd C, Sällström J, Wilander E and Rylander E:
Adenocarcinoma of the uterine cervix: The presence of human
papillomavirus and the method of detection. Acta Obstet Gynecol
Scand. 82:960–965. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dahlström L, Ylitalo N, Sundström K,
Palmgren J, Ploner A, Eloranta S, Sanjeevi C, Andersson S, Rohan T,
Dillner J, et al: Prospective study of human papillomavirus and
risk of cervical adenocarcinoma. Int J Cancer. 127:1923–1930. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dillner J: Covid-19: Challenges and
opportunities for cancer screening: An example from cervical cancer
in Sweden. International Agency for Research on Cancer COVID-19 and
cancer screening. May;2021.
|
|
43
|
de Pelsemaeker MC, Guiot Y, Vanderveken J,
Galant C and Van Bockstal M: The impact of the COVID-19 pandemic
and the associated Belgian governmental measures on cancer
screening, surgical pathology and cytopathology. Pathobiology.
88:46–55. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Feletto E, Grogan P, Nickson C, Smith M
and Canfell K: How has COVID-19 impacted cancer screening?
Adaptation of services and the future outlook in Australia. Public
Health Res Pract. 30:e30420262020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kregting LM, Kaljouw S, de Jonge L, Jansen
EEL, Peterse EFP, Heijnsdijk EAM, van Ravesteyn NT,
Lansdorp-Vogelaar I and de Kok IMCM: Effects of cancer screening
restart strategies after COVID-19 disruption. Br J Cancer.
12:1516–1523. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Miller M, Xu L, Qin J, Hahn E, Ngo-Metzger
Q, Mittman B, Tewari D, Hodeib M, Wride P, Saraiya M and Chao CR:
Impact of COVID-19 on cervical cancer screening rates among women
aged 21–65 in a large integrated health care system-Southern
California January 1-September 30, 2019 and January 1-September 30,
2020. MMWR Morb Mortal Wkly Rep. 70:109–113. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gorin SNS, Jimbo M, Heizelman R, Harmes K
and Harper D: The future of cancer screening after COVID-19 may be
at home. Cancer. 127:498–503. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Burger E, Jansen E, Killen J, de Kok U,
Smith M, Sy S, Dunnewind N, Campos N, Haas J, Kobrin S, et al:
Impact of COVID-19-related care disruptions on cervical cancer
screening in the United States. J Med Screen. 28:213–216. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Nogami Y, Kobayashi Y, Tsuji K, Yokota M,
Nishio H, Nakamura M, Yamagami W, Morisada T, Tominaga E, Banno K
and Aoki D: Impact of the COVID-19 epidemic at a high-volume
facility in gynecological oncology in Tokyo, Japan: A single-center
experience. J Ovarian Res. 13:1052020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ajenifuja K, Belinson J, Goldstein A,
Desai K, de Sanjose S and Schiffman M: Designing low-cost, accurate
cervical screening strategies that take into account COVID-19: A
role for self-sampled HPV typing. Infect Agent Cancer. 15:612020.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ciavattini A, Carpini G, Giannella L,
Arbyn M, Kyrgiou M, Joura E, Sehouli J, Carcopino X, Redman C,
Nieminen P, et al: European Federation for Colposcopy (EFC) and
European Society of Gynaecological Oncology (ESGO) joint
considerations about human papillomavirus (HPV) vaccination,
screening programs, colposcopy, and surgery during and after the
COVID-19 pandemic. Int J Gynecol Cancer. 30:1097–1100. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cohen M, Powell A, Coleman J, Keller J,
Livingston A and Anderson J: Special ambulatory gynecologic
considerations in the era of coronavirus disease 2019 (COVID-19)
and implications for future practice. Am J Obstet Gynecol.
223:372–378. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Feldman S and Haas J: How the corona
disease-2019 may improve care: Rethinking cervical cancer
prevention. J Natl Cancer Inst. 113:djaa0892020.
|
|
54
|
Arbyn M, Verdoodt F, Snijders P, Verhoef
V, Suonio E, Dillner L, Minozzi S, Bellisario C, Banzi R, Zhao FH,
et al: Accuracy of human papillomavirus testing on self-collected
versus clinician-collected samples: A meta-analysis. Lancet Oncol.
15:172–183. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Arbyn M, Snijders PJ, Meijer CJ, Berkhof
J, Cuschieri K, Kocjan BJ and Poljak M: Which high-risk HPV assays
fulfill criteria for use in primary cervical cancer screening? Clin
Microbiol Infect. 21:817–826. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Jentschke M, Chen K, Arbyn M, Hertel B,
Noskowicz M, Soergel P and Hillemans P: Direct comparison of two
vaginal self-sampling devices for the detection of human
papillomavirus infections. J Clin Virol. 82:46–50. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bergengren L, Kaliff M, Larsson G,
Karlsson M and Helenius G: Comparison between professional sampling
and self-sampling for HPV-based cervical cancer screening among
postmenopausal women. Int J Gynecol Obstet. 142:359–364. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Östensson E, Hellström AC, Hellman K,
Gustavsson I, Gyllensten U, Wilander E, Zethraeus N and Andersson
S: Projected cost-effectiveness of repeat high-risk human
papillomavirus testing using self-collected vaginal samples in the
Swedish cervical cancer screening program. Acta Obstet Gynecol
Scand. 92:830–840. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Galbraith KV, Gilkey MB, Smith JS, Richman
AR, Barclay L and Brewer NT: Perceptions of mailed HPV self-testing
among women at higher risk for cervical cancer. J Community Health.
39:849–856. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Arrossi S, Ramos S, Straw C, Thouyaret L
and Orellana L: HPV testing: A mixed-method approach to understand
why women prefer self-collection in a middle-income country. BMC
Public Health. 16:8322016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Racey C and Gesink D: Barriers and
facilitators to cervical cancer screening among women in rural
Ontario, Canada: The role of self-collected HPV testing. J Rural
Health. 32:136–145. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Mao C, Kulasingam S, Whitham H, Hawes S,
Lin J and Kiviat N: Clinician and patient acceptability of
self-collected human papillomavirus testing for cervical cancer
screening. J Womens Health. 26:609–615. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Andersson S, Belkić K, Mints M and
Östensson E: Acceptance of self-sampling among long-term cervical
screening non-attenders with HPV positive results: Promising
opportunity for specific cancer education. J Cancer Educ.
36:126–133. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Lindström AK, Hermansson RS, Gustavsson I,
Hedlund Lindberg J, Gyllensten U and Olovsson M: Cervical dysplasia
in elderly women performing repeated self-sampling for HPV testing.
PLoS One. 13:e02077142018. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Foster E, Malloy M, Jokubaitis V, Wrede D,
Butzkueven H, Sasadeusz J, Van Doornum S, Macrae F, Unglik G,
Brotherton J and van der Walt A: Increased risk of cervical
dysplasia in females with autoimmune conditions-results from an
Australia database linkage study. PLoS One. 15:e02348132020.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Jentschke M, Kampers J, Becker J,
Sibbertsen P and Hillemanns P: Prophylactic HPV vaccination after
conization: A systematic review and meta-analysis. Vaccine.
38:6402–6409. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Joharinia N, Faghihinezhad S, Seyedi K,
Farhadi A, Hosseini SY, Safaei A, Baharampour H and Sarvari J:
Co-existing of HSV1/2 or EBV infection with the presence of
high-risk HPV DNA in cervical lesions in the southwest of Iran.
Asian Pac J Cancer Prev. 21:1459–1464. 2020. View Article : Google Scholar : PubMed/NCBI
|
